

## Hull and East Riding Prescribing Committee Minutes – Unconfirmed

<b>Date / Time</b>	Wednesday 26 <sup>th</sup> January 2022, 1pm
<b>Venue</b>	WEBEX
<b>Chair</b>	Dr S Raise, GP Prescribing Lead, ER
<b>Notes / Action Points</b>	Miss J Morgan
<b>Quorate: Yes / No</b>	Yes – after 1:30
	Miss J Morgan, Principal Pharmacist, HUTH Dr B Ali, GP Prescribing Lead, ER CCG Mrs E Baggaley, Head of Medicines Service, CHCP Mr K McCorry, Senior Pharmacist, NECS Ms M Opoku-Fofie, Deputy Chief Pharmacist, HFTH Prof A Morice, Professor of Respiratory Medicine, HUTH Mrs C Haywood, Professional Development Lead, LPC Mrs E Wise, Pharmacy Manager, Spire Hull and East Riding Dr Zoe Norris, Humber LMC
<b>Apologies</b>	Mr P Davis, Strategic Lead Primary Care, Hull, CCG  Dr R Schreiber, Professional Secretary LMC  Ms J Goode, Chief Pharmacist, HUTH
<b>In attendance</b>	Luke Storr, Interface Technician, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2022.01.01	Apologies	As above				
2022.01.02	Declarations of Interest	None				
2022.01.03	Minutes of the Previous Meeting	Accepted as a true record				
2022.01.04	Matters Arising & Action Tracker	<b>Correspondence Received</b> JM still working with rheumatology to prepare pathway with rituximab without MTX. JM received text pathway awaiting flowcharts	Ongoing	Update next time	JM	Nov 21
		<b>Feedback From Commissioning Groups</b> KMc and JM to work with CCG to approve MS guideline JM to chase about attending MS meeting	Ongoing	Update next time	JM	
		<b>Hydroxychloroquine SCF</b> Mr Vize sent JM update pathway that matches Harrogate pathway but not been commissioned in this version. JM suggested to wait until updated pathway is published. To add to agenda when pathway published	Ongoing	Update next time	JM	Mar 22
		<b>Traffic Light status</b> JM to update formulary and red list- Updated	Action complete	No further actions	JM	Jan22
		<b>Prescribing guidelines, shared care frameworks for approval</b> JM to update approved guidelines on HERPC website. JM updated most of guidance and added to HERPC other than anticoagulant and rosacea. Actions below	Action complete	No further action	JM	Jan 22
		<b>Prescribing guidelines, shared care frameworks for approval</b> JM confirmed with RS LMC position on antenatal and postnatal				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>dalteparin. JM to update commissioning position of anticoagulants to reflect position on antenatal and postnatal care. JM discussed with family and womens pharmacy lead and to contact obstetric led</p> <p><b>Prescribing guidelines, shared care frameworks for approval</b> JM to update rosacea pathway regarding referral to secondary care for transient facial flushing. Pathway update to be uploaded to HERPC website</p> <p><b>AOB</b> Diabetes guideline – JM to review diabetes guideline when NICE publish and discuss with Diabetologists</p>	<p>New action</p> <p>To upload</p> <p>Ongoing</p>	<p>JM to contact Dr Rajesh</p> <p>To upload</p> <p>To review guideline update</p>	<p>JM</p> <p>JM</p> <p>JM</p>	<p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p>
2022.01.05	Traffic Light Status	<p>Tebentafusp- Discussed, proposed as RED</p> <p>Accrete D3- added to HUTH formulary, proposed as GREEN</p> <p>Calcichew D3 forte- removed from HUTH formulary</p> <p>Apalutamide- approved as per TA740/741, proposed as RED</p>	Approved	RED list to be updated and joint formulary to be updated	LS	Mar 22
2022.01.06	Feedback From Commissioning Groups	<p>All previous guidelines/SCF have now been approved.</p> <p>DOAC- Both Hull and East Riding of Yorkshire CCGs will go with national schemes</p>	Noted	No further action		Jan 22
2022.01.07	Prescribing guidelines, shared care frameworks for approval	<p><b>NEW</b></p> <p><b>a) UTI guidance</b> JM presented the updated UTI guidance that has been approved at ACAT. This is based on the NICE guidance. Both SR and KMc raised the significant changes from previous local guidance and increased recommendations for quinolones and cephalosporins.</p> <p><b>b) Dienogest Pathway</b> JM presented the new pathway for management of endometriosis including dienogest. SR questioned who prescribes the initial prescription and then the cascade onwards. JM to confirm with specialist team</p> <p><b>c) Secondary prevention pathways for lipid lowering therapies</b> JM presented the new secondary prevention of pathway for lipid lowering therapies. This has been prepared by the HUTH lipid clinic including inclisiran. Within the pathway it is recommended</p>	<p>Approved</p> <p>Clarification on pathway</p> <p>Clarification on pathway</p>	<p>To remove old UTI section and upload update.</p> <p>JM to confirm with specialised service</p> <p>JM to confirm with specialised service</p>	<p>JM/LS</p> <p>JM</p> <p>JM</p>	<p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>that in the short term inclisiran is started in secondary care and NHSE have now produced guidance on how to claim the price difference from buying in primary care from them. ZN suggested that a shared care should be developed to provide further information to GPs to support prescribing and monitoring of therapy. BA raised that LDL-C measurements that require fasting. JM to feedback to lipid team and draft shared care framework.</p> <p><b>d) Renal analgesic ladder (updated)</b> Previously discussed at meeting and updates added following feedback to specialist team – adding specific information about when NSAIDs can be used and confirmed that codeine not appropriate, as extra monitoring needed.</p> <p><b>UPDATES</b></p> <p><b>a) Ticagrelor (60mg) for preventing atherothrombotic events after myocardial infarction</b> JM presented this guideline, which had been reviewed by the cardiology lead pharmacist. There had been no changes in content. SR questioned how prescribers would know that patients were for this therapy; JM confirmed cardiology clearly communicate this when using this strength of ticagrelor</p> <p><b>b) Prescribing medicines in pregnancy</b> JM had updated the medicines for management of common conditions; in updating this found the Specialist Pharmacy Service (SPS) had prepared some similar work. JM proposed that the HERPC page linked through to the SPS guidance rather than updating the HERPC guidance. This was approved; JM to update HERPC webpage. KMc raised that multiple links to HUTH guidelines are linked on this page JM to add that these are information only and not approved by HERPC.</p> <p><b>c) Renal transplant medicines</b> Covid-19 vaccine added and alternative H2 receptor antagonist. Immunosuppressant section to be updated</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>Add to HERPC website</p> <p>Update on webpage</p> <p>Update webpage</p>	<p>JM</p> <p>JM/LS</p> <p>JM</p>	<p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p>
2022.01.08	MHRA DSU	<p><b>November 2021</b> Yellow fever: vaccine checklist Adrenaline auto injectors: Reminder for prescribers to support safe and effective use Covid-19 update</p>	Noted	No further action		Jan 22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p><b>December 2021</b></p> <p>Haloperidol: risk when used in elderly patients for acute treatment of delirium</p> <p>Venetoclax: updated recommendations on tumour lysis syndrome</p> <p>Dapagliflozin: no longer authorised for treatment of type 1 diabetes mellitus</p> <p>Covid-19 update</p>				
2022.01.09	<b>Regional Medicines Optimisation Committee</b>	Nil this month	Noted	No further action		Jan 22
2022.01.10	<b>Correspondence Received</b>	<ul style="list-style-type: none"> <li><b>Equivalent doses of oral benzodiazepines</b></li> </ul> <p>Humber DTG approved document with the half-life of benzodiazepines, easier to prescribe when switching</p> <ul style="list-style-type: none"> <li><b>National procurement for direct acting oral anticoagulants</b></li> </ul> <p>JM presented the national procurement for DOACs, NHSE have procured DOACs at a national level and the document proposes that edoxaban should be the first choice DOAC. The potential savings that could generated from working towards this document were highlighted by KMc. JM confirmed that HUTH D&amp;T will discuss at next meeting; however risks at transfer of care so unlikely that will recommend blanket switching.</p>	Noted	No further action		Jan 22
2022.01.11	<b>Primary Care Rebate Scheme</b>	<p>ERoY CCG</p> <p>(a) DOAC</p> <p>Hull CCG</p> <p>(a) DOAC</p>	Noted	No further action		Jan 22
2022.01.12	<b>Additional Minutes for Information</b>	<p>a) MMIG (Nov + Dec)</p> <p>b) HUTH D&amp;T (Nov + Dec)</p> <p>c) HTFT DTC (Sept)</p> <p>d) CHCP</p> <p>e) Formulary Sub Group</p> <p>f) Hull CC Planning &amp; Commissioning (Sept)</p>	Noted	No further action		Jan 22
2022.01.13	<b>A.O.B</b>					
	<b>Date and Time of</b>	Wednesday 23 <sup>rd</sup> March 2022, 1pm, WEBEX				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
	<b>Next Meeting</b>					